WallStSmart

ImmuCell Corporation (ICCC)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 2045% more annual revenue ($606.42M vs $28.27M). ICCC leads profitability with a 6.2% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

ICCC

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 5.0Value: 5.7Quality: 8.5
Piotroski: 6/9Altman Z: 1.52

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICCCSignificantly Overvalued (-353.9%)

Margin of Safety

-353.9%

Fair Value

$1.43

Current Price

$6.44

$5.01 premium

UndervaluedFair: $1.43Overvalued

Intrinsic value data unavailable for INSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICCC2 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
17.8%8/10

17.8% revenue growth

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ICCC4 concerns · Avg: 3.5/10
P/E RatioValuation
28.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.524/10

Distress zone — elevated risk

Market CapQuality
$54.73M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ICCC

The strongest argument for ICCC centers on Price/Book, Revenue Growth. Revenue growth of 17.8% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ICCC

The primary concerns for ICCC are P/E Ratio, Altman Z-Score, Market Cap.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ICCC profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

ICCC is growing revenue faster at 17.8% — sustainability is the question.

ICCC generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ImmuCell Corporation

HEALTHCARE · BIOTECHNOLOGY · USA

ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?